Abstract | BACKGROUND: METHODS AND RESULTS: The association between age and the primary composite outcome, as well as major bleeding were evaluated in the PLATelet inhibition and patient Outcomes (PLATO) trial using Cox proportional hazards. Similar models were used to evaluate the interaction of age with treatment effects. Hazard ratios were adjusted for baseline characteristics. The clinical benefit of ticagrelor over clopidogrel was not significantly different between patients aged ≥75 years of age (n=2878) and those <75 years of age (n=15 744) with respect to the composite of cardiovascular death, myocardial infarction, or stroke (interaction P=0.56), myocardial infarction (P=0.33), cardiovascular death (P=0.47), definite stent thrombosis (P=0.81), or all-cause mortality (P=0.76). No increase in PLATO-defined overall major bleeding with ticagrelor versus clopidogrel was observed in patients aged ≥75 years (hazard ratio, 1.02; 95% confidence interval, 0.82-1.27) or patients aged <75 years (hazard ratio, 1.04; 95% confidence interval, 0.94-1.15). Dyspnea and ventricular pauses were more common during ticagrelor than clopidogrel treatment, with no evidence of an age-by-treatment interaction. CONCLUSIONS:
|
Authors | Steen Husted, Stefan James, Richard C Becker, Jay Horrow, Hugo Katus, Robert F Storey, Christopher P Cannon, Magda Heras, Renato D Lopes, Joao Morais, Kenneth W Mahaffey, Richard G Bach, Daniel Wojdyla, Lars Wallentin, PLATO study group |
Journal | Circulation. Cardiovascular quality and outcomes
(Circ Cardiovasc Qual Outcomes)
Vol. 5
Issue 5
Pg. 680-8
(Sep 01 2012)
ISSN: 1941-7705 [Electronic] United States |
PMID | 22991347
(Publication Type: Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Platelet Aggregation Inhibitors
- Clopidogrel
- Ticagrelor
- Adenosine
- Ticlopidine
|
Topics |
- Acute Coronary Syndrome
(blood, complications, drug therapy, mortality)
- Adenosine
(adverse effects, analogs & derivatives, therapeutic use)
- Age Factors
- Aged
- Cardiovascular Diseases
(etiology, mortality, prevention & control)
- Chi-Square Distribution
- Clopidogrel
- Double-Blind Method
- Female
- Hemorrhage
(chemically induced)
- Humans
- Kaplan-Meier Estimate
- Male
- Patient Safety
- Percutaneous Coronary Intervention
(adverse effects, instrumentation)
- Platelet Aggregation
(drug effects)
- Platelet Aggregation Inhibitors
(adverse effects, therapeutic use)
- Proportional Hazards Models
- Prospective Studies
- Risk Assessment
- Risk Factors
- Stents
- Ticagrelor
- Ticlopidine
(adverse effects, analogs & derivatives, therapeutic use)
- Time Factors
- Treatment Outcome
|